Management of GLP-1 receptor agonist therapy in reproductive-aged patients
On the community-reported low-dose protocol (~50mcg/day loading, then 250mcg 1-2/week), only about 1-2mg of mass is used in any 28-day window so every common vial holds far more than the window allows, and the window, not the dose, is always the limiter: Practical implication: because so little is used per 28-day window, a 5mg vial or staged reconstitution of a larger vial minimizes waste
While compounded drugs are sometimes prescribed for those who have unique needs or can't access brand-name drugs, it's important to know that these medications are not FDA-approved, meaning they are not reviewed for safety or efficacy before being marketed
Sales of diabetes and weight-loss drugs have been a boon to pharmacies, too, and fueled the growth of virtual services from upstarts and even established players like Shoppers Drug Mart
Growing evidence suggests that GLP-1 RA has the potential to treat neurodegenerative diseases, particularly in diabetes-related Alzheimers disease (AD) and Parkinsons disease (PD)
Continue Reading